Evidence map›Paper›PMID 40849656›Full record

ArticleActa neuropathologica communications2025

H3F3B p.K27I-mutant diffuse midline glioma is a distinct subtype of H3K27-altered diffuse midline glioma.

Lei Cheng, Min Zhou, Tao Luo, Rongfang Dong, Ni Chen, Xinyong Cai, Xingwen Wang, Hao Wu, Zan Chen, Zuowei Wang and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta neuropathologica communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Lei Cheng *Department of Neurosurgery, Xuanwu Hospital, International Neuroscience Institute, Capital Medical University, #45 Changchun Street, Western District, Beijing, 100053, China.
Min Zhou *Department of Pathology, Xuanwu Hospital, Capital Medical University, #45 Changchun Street, Western District, Beijing, 100053, China.
Tao LuoInstitute of Pathology and Southwest Cancer Center, Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing, 400038, China.
Rongfang DongBeijing Jishuitan Hospital, Capital Medical University, Beijing, 100035, China.
Ni ChenLaboratory of Pathology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Xinyong CaiBuping Medical Laboratory Co. Ltd (BP Health), Hangzhou, China.
Xingwen WangDepartment of Neurosurgery, Xuanwu Hospital, International Neuroscience Institute, Capital Medical University, #45 Changchun Street, Western District, Beijing, 100053, China.
Hao WuDepartment of Neurosurgery, Xuanwu Hospital, International Neuroscience Institute, Capital Medical University, #45 Changchun Street, Western District, Beijing, 100053, China.
Zan ChenDepartment of Neurosurgery, Xuanwu Hospital, International Neuroscience Institute, Capital Medical University, #45 Changchun Street, Western District, Beijing, 100053, China.
Zuowei WangDepartment of Neurosurgery, Xuanwu Hospital, International Neuroscience Institute, Capital Medical University, #45 Changchun Street, Western District, Beijing, 100053, China.
Xueling QiDepartment of Pathology, Sanbo Brain Hospital, Capital Medical University, Beijing, 100093, China.
Dehong LuDepartment of Pathology, Xuanwu Hospital, Capital Medical University, #45 Changchun Street, Western District, Beijing, 100053, China.
Lianghong TengDepartment of Pathology, Xuanwu Hospital, Capital Medical University, #45 Changchun Street, Western District, Beijing, 100053, China. tenglianghong@xwhosp.org.
Fengzeng JianDepartment of Neurosurgery, Xuanwu Hospital, International Neuroscience Institute, Capital Medical University, #45 Changchun Street, Western District, Beijing, 100053, China. jianfengzeng@xwh.ccmu.edu.cn.
Leiming WangDepartment of Pathology, Xuanwu Hospital, Capital Medical University, #45 Changchun Street, Western District, Beijing, 100053, China. Wangleiming0918@163.com.

Funding

Beijing Nova program Z201100006820149Natural Science Foundation of Beijing Municipality,China 7254365The capital health research and development of special 2022-2-2015
6 · The paper itself

Abstract

H3K27-altered diffuse midline glioma (DMG) is a fatal disease, including four subtypes H3.3-mutant, H3.1/H3.2-mutant, H3-wildtype with EZHIP overexpression, and EGFR-mutant. H3F3B, another gene encoding histone H3.3 in addition to H3F3A, was ever reported to be mutated in DMGs. However, the clinical and molecular characteristics of H3F3B-mutant DMGs is yet understood. The clinical and radiological information of 9 patients with H3F3B-mutant DMG were retrospectively collected. Tumor specimens underwent DNA methylation profiling and next-generation sequencing. All tumors harbored somatic H3F3B p.K27I mutation. Average patient age was 46 ± 6.86 years, 6 tumors located in spinal cord, 5 tumors involved brainstem and 2 arose in the thalamus. Immunohistochemistry showed these tumors exhibited completely or mosaic-like loss of H3K27me3 expression. Unsupervised t-distributed stochastic neighbor embedding (t-SNE) analysis of DNA methylation profiles showed that H3F3B-mutant DMGs formed a unique methylation cluster separate from other gliomas with H3K27me3 loss and DMGs with canonical histone H3 mutation. PPM1D and NF1 were frequently mutated in H3F3B-mutant DMGs. Survival analysis showed that H3F3B-mutant DMGs had poor prognosis comparable to H3K27M-mutant DMGs. Taken together, H3F3B mutation also cause a loss of H3K27 trimethylation in DMGs and result in poor prognosis. The distinct characteristics of DNA methylation and mutational spectrum between H3F3B-mutant DMGs and canonical H3K27M-mutant DMGs might suggest divergent underlying mechanism of gliomagenesis.

Indexed as

Brain NeoplasmsGliomaHistonesAdultDNA MethylationFemaleHumansMaleMiddle AgedMutationRetrospective StudiesHistonesDiffuse midline gliomaDNA mutationH3F3BHistone H3Methylation

Identifiers

PMID40849656
PMCPMC12374277

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.